I have been hesitant about buying into Progenics Pharmaceuticals (PGNX) due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena. Perhaps it is all the hype of immuno-oncology and the rise of gene therapy that caused me to believe that radiopharmaceuticals is an antiquated technology and destined to be in the dumpster. I always viewed PGNX as a company attempting to have a niche with an old practice yet was going to compete in a world of cutting-edge therapies. As a result, I had very little conviction that clinicians